Investor Alert: Kaplan Fox Investigates AbbVie Inc.

Wednesday, September 19, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Sept. 19, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com)

has been investigating claims on behalf of investors of AbbVie Inc. ("AbbVie" or the "Company"). 

On September 18, 2018, Reuters reported that California Insurance Commissioner Dave

Jones filed a complaint on behalf of the State of California against AbbVie alleging the "drugmaker gave illegal kickbacks to healthcare providers to prescribe its blockbuster drug, Humira."  The regulator alleged that AbbVie "engaged in a far-reaching scheme including cash, meals, drinks, gifts, trips and patient referrals, as well as free and valuable professional goods and services to physicians to induce and reward Humira prescriptions."  

The case filed in Alameda County Superior Court, California alleges that private insurers have paid out $1.2 billion in Humira-related pharmacy claims.  The allegations of AbbVie's alleged misconduct were brought to the attention of the department by a whistleblower, a registered nurse who was employed as an AbbVie Nurse Ambassador in Florida.

On September 18, 2018, AbbVie shares declined from a closing price on September 17, 2018 of $95.37 per share, to close at $92.61 per share, a decline of $2.76 per share, or approximately 3%, on heavier than usual volume. 

If you are an investor in AbbVie and would like to discuss our investigation, please contact us by emailing jcampisi@kaplanfox.com or by calling 800-290-1952. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about this Notice, the action, your rights, or your interests, please contact:

Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP850 Third Avenue, 14th FloorNew York, New York 10022(800) 290-1952(212) 687-1980Fax: (212) 687-7714E-mail: jcampisi@kaplanfox.com

Laurence D. KingKAPLAN FOX & KILSHEIMER LLP350 Sansome Street, Suite 400 San Francisco, California  94104(415) 772-4700Fax:  (415) 772-4707E-mail: lking@kaplanfox.com

 

Cision View original content:http://www.prnewswire.com/news-releases/investor-alert-kaplan-fox-investigates-abbvie-inc-300715382.html

SOURCE Kaplan Fox & Kilsheimer LLP



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store